Ophthalmology specialty
Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###
Merck & Co., EyeBio, Ophthalmology, Trispecific antibody, Restoret, Acquisition, Biotechnology, Pharmaceuticals
FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology
FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval